Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M32.5Revenue (TTM) $M0.1Net Margin (%)-32,717.1Altman Z-Score-20.3
Enterprise Value $M16.8EPS (TTM) $-2.3Operating Margin %-30,746.7Piotroski F-Score1
P/E(ttm)--Beneish M-Score-1.9Pre-tax Margin (%)-32,717.1Higher ROA y-yN
Price/Book3.910-y EBITDA Growth Rate %--Quick Ratio5.3Cash flow > EarningsY
Price/Sales3625-y EBITDA Growth Rate %--Current Ratio5.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-97.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-182.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARDM

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARDMJohn Paulson 2016-09-30 Add0.01%$4.13 - $6.88
($4.86)
$ 2.17-55%Add 122.93%146,918
ARDMJohn Paulson 2016-06-30 Add$4.18 - $5.13
($4.53)
$ 2.17-52%Add 235.18%65,903
ARDMJohn Paulson 2016-03-31 Buy $2.65 - $4.44
($3.45)
$ 2.17-37%New holding19,662
ARDMFirst Eagle Investment 2014-06-30 Buy 0.08%$0.185 - $9.52
($3.37)
$ 2.17-36%New holding3,854,730
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARDM is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARDM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Froehlich Juergen KurtChief Medical Officer 2016-10-04Sell423$6.76-67.9view
Froehlich Juergen KurtChief Medical Officer 2016-06-21Sell333$4.45-51.24view
THOMPSON VIRGILDirector 2013-12-13Sell84$6.8-68.09view
Grifols SADirector, 10% Owner 2013-08-27Sell0$0-68.09view
Boxer Capital, LLC10% Owner 2013-05-20Sell0$0-68.09view
DEF Associates Ltd.See footnote below 2012-01-01Sell0$0-68.09view
DEF Associates LPSee Footnote 1 below 2010-12-31Sell0$0-68.09view
First Eagle Value in BiotechnoSee remarks. 2009-02-23Sell0$0-68.09view
First Eagle Value in Biotechno10% Owner 2009-02-23Sell0$0-68.09view
Grimes D JefferyVP Legal Affairs, Secretary 2008-07-01Sell0$0-68.09view

Quarterly/Annual Reports about ARDM:

News about ARDM:

Articles On GuruFocus.com
First Eagle Adds to Stake in Aradigm Apr 28 2016 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 
Eveillard’s First Eagle Seizes 45% of Pharamaceutical Company, Aradigm Dec 19 2012 

More From Other Websites
Aradigm Lung Infection Antibiotic Fails Trial (ARDM) Dec 02 2016
Don’t Write Off Aradigm Corporation (ARDM) Just Yet Dec 02 2016
Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
Aradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials Dec 01 2016
Aradigm posts mixed late-stage data on inhaled antibiotic Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
ARADIGM CORP Financials Nov 18 2016
ARADIGM CORP Files SEC form 10-Q, Quarterly Report Nov 10 2016
Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Nov 10 2016
Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16 Nov 10 2016
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 09 2016
Aradigm Announces Third Quarter 2016 Financial Results Nov 09 2016
Aradigm reports 3Q loss Nov 09 2016
Aradigm reports 3Q loss Nov 09 2016
Aradigm Announces Third Quarter 2016 Financial Results Nov 09 2016
Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm's Inhaled Ciprofloxacin Oct 18 2016
Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm’s Inhaled Ciprofloxacin Oct 18 2016
Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm’s Inhaled Ciprofloxacin Oct 18 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)